相关实验视频
Updated: Jan 12, 2026

08:05
Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
41.2K
在B.uniformis IM01衍生IAA通过AhR/NLRP3通路在小鼠中缓解喘
Yujia He1, Tao Yang1, Jielan Mi1,2
1National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Cellular and molecular life sciences : CMLS
|November 6, 2025
概括
巴克特罗伊德斯uniformis IM01通过促进英多尔-3-酸 (IAA) 生产来缓解过敏性喘. 这种益生菌激活阿里碳化合物受体 (AhR),减少炎症并改善肠肺轴功能.
科学领域:
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 肠道微生物群在过敏疾病的发病过程中发挥着作用.
- 细菌类物种在管理过敏方面表现出潜力.
- 在过敏性喘中,Bacteroides uniformis的具体机制尚不清楚.
研究的目的:
- 在小鼠模型中研究 Bacteroides uniformis IM01 对过敏性喘的影响.
- 阐明B. uniformis IM01在改善喘症状中的潜在机制.
主要方法:
- 用B. uniformis IM01口服给一个小鼠喘模型.
- 测量英多尔-3-酸 (IAA) 的水平.
- 分析呼吸道炎症,T助手2 (Th2) 免疫反应和上皮屏障功能.
- 研究托代谢,阿里碳水化合物受体 (AhR) 激活,IL-22产生,NF-κB/NLRP3信号传递和调控性T细胞 (Treg) 分化.
主要成果:
- B. uniformis IM01的使用显著增加了IAA的产量.
- 治疗抑制了呼吸道炎症和Th2免疫反应.
- 在喘模型中,上皮质屏障功能得到了改善.
- B. uniformis IM01上调了托代谢,导致IAA,AhR激活和IL-22的产生增加.
- 激活的AhR抑制了NF-κB/NLRP3信号传递,并促进了Treg分化,改善了喘症状.
结论:
- B. uniformis IM01通过增强IAA的产生和激活AhR来改善过敏性喘.
- 肠肺轴是通过B. uniformis IM01发挥其治疗作用的关键途径.
- 针对肠道微生物群,特别是B. uniformis,为过敏性喘提供了一个潜在的治疗策略.
更多相关视频
相关概念视频
Asthma-II: Pathophysiology and Classification
4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Asthma-I: Introduction
3.3K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.3K
Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Drugs Used in Lower Respiratory Disorders: Overview
1.0K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.0K

